SOME COAGULATION PARAMETERS AND INFLAMMATORY MARKERS IN DIABETIC PATIENTS WITH COVID-19 PNEUMONIA

Thị Hằng Nguyễn1,, Hoàn Lê2
1 HMU
2 Hanoi Medical University Hospital

Main Article Content

Abstract

Objective: To characterize some coagulation parameters and inflammatory markers at the time of hospital admission in diabetic patients with COVID-19 pneumonia. Material and method: Retrospective study on 242 diabetic patients with COVID-19 pneumonia classified by disease severity (according to the Ministry of Health's criteria for classifying COVID-19 severity) as mild, moderate, severe, critical at hospital treating COVID-19 patients from September 2021 to April 2022. Result: Mean age was 72.6 years old, of which 30.2% of patients were >80 years old, mainly patients with type 2 diabetes accounted for 95.9%, the most common comorbidities was hypertension accounted for 74.8%. The index of Fibrinogen, D-Dimer, CRP, LDH, ferritin at hospital admission of mild and moderate was lower than that of severe and critical group, significantly different with p<0.05. Conclusion: At admission, the coagulation indices and inflammatory markers such as D-Dimer, Fibrinogen, Ferritin, LDH, CRP hs are significant in assessing and predicting the treatment outcome of patients with diabetes mellitus with pneumonia. COVID-19 with a mortality rate of 21.5%.

Article Details

References

1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-733. doi:10.1056/NEJMoa2001017
2. Kadiane-Oussou NJ, Klopfenstein T, Royer PY, Toko L, Gendrin V, Zayet S. COVID-19: comparative clinical features and outcome in 114 patients with or without pneumonia (Nord Franche-Comte Hospital, France). Microbes Infect. 2020; 22(10):622-625. doi:10.1016/j micinf.2020.10.002
3. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID‐19. Diabetes Metab Res Rev. 2020;36(7):e3319. doi:10.1002/dmrr.3319
4. Holman N, Knighton P, Kar P, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study. Lancet Diabetes Endocrinol. 20208(10):823-833. doi:10.1016/ S2213-8587(20)30271-0
5. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135(23):2033-2040. doi:10.1182/ blood.2020006000
6. Guo W, Li M, Dong Y, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36(7): e3319. doi:10.1002/dmrr.3319
7. Bivona G, Agnello L, Ciaccio M. Biomarkers for Prognosis and Treatment Response in COVID-19 Patients. Ann Lab Med. 2021;41(6):540-548. doi:10.3343/alm.2021.41.6.540
8. Thompson S, Bohn MK, Mancini N, et al. IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients. Clinical Chemistry and Laboratory Medicine (CCLM). 2020; 58(12):2009-2016. doi:10.1515/cclm-2020-1414
9. Bode B, Garrett V, Messler J, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19
10. Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020;14(4):813-821. doi:10.1177/1932296820924469